HomeCompareOLYMY vs MRK

OLYMY vs MRK: Dividend Comparison 2026

OLYMY yields 1.49% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLYMY wins by $19.35M in total portfolio value· pulled ahead in Year 3
10 years
OLYMY
OLYMY
● Live price
1.49%
Share price
$9.37
Annual div
$0.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.41M
Annual income
$17,198,899.56
Full OLYMY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — OLYMY vs MRK

📍 OLYMY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLYMYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLYMY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLYMY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLYMY
Annual income on $10K today (after 15% tax)
$127.00/yr
After 10yr DRIP, annual income (after tax)
$14,619,064.63/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, OLYMY beats the other by $14,610,736.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLYMY + MRK for your $10,000?

OLYMY: 50%MRK: 50%
100% MRK50/50100% OLYMY
Portfolio after 10yr
$9.73M
Annual income
$8,604,348.85/yr
Blended yield
88.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OLYMY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.3
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLYMY buys
0
MRK buys
0
No recent congressional trades found for OLYMY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLYMYMRK
Forward yield1.49%2.76%
Annual dividend / share$0.14$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$19.41M$56.8K
Annual income after 10y$17,198,899.56$9,798.13
Total dividends collected$19.21M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: OLYMY vs MRK ($10,000, DRIP)

YearOLYMY PortfolioOLYMY Income/yrMRK PortfolioMRK Income/yrGap
1$10,999$298.83$11,206$366.19$207.00MRK
2$12,383$614.34$12,650$502.35$267.00MRK
3← crossover$14,543$1,292.83$14,407$694.19+$136.00OLYMY
4$18,399$2,837.94$16,585$967.82+$1.8KOLYMY
5$26,398$6,711.03$19,342$1,363.89+$7.1KOLYMY
6$46,243$17,997.57$22,913$1,947.19+$23.3KOLYMY
7$108,411$58,930.72$27,662$2,823.89+$80.7KOLYMY
8$374,234$258,234.50$34,159$4,173.35+$340.1KOLYMY
9$2,066,647$1,666,216.42$43,337$6,308.80+$2.02MOLYMY
10$19,410,212$17,198,899.56$56,776$9,798.13+$19.35MOLYMY

OLYMY vs MRK: Complete Analysis 2026

OLYMYStock

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.

Full OLYMY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this OLYMY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLYMY vs SCHDOLYMY vs JEPIOLYMY vs OOLYMY vs KOOLYMY vs MAINOLYMY vs JNJOLYMY vs ABBVOLYMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.